Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Dose-finding Study to Assess the Safety and Immunogenicity of an Orf Virus-based COVID-19 Vaccine Booster (Prime-2-CoV_Beta) in Healthy Adults

NCT05389319 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT05389319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05389319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Dose-finding Study to Assess the Safety and Immunogenicity of an Orf Virus-based COVID-19 Vaccine Booster (Prime-2-CoV_Beta) in Healthy Adults
Lead sponsor
University Hospital Tuebingen
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 24, 2022
Completion date
December 31, 2026
Enrollment
96 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19